• Home
  • Search
  • When Potency Is Not Enough: Aligning Modality, Exposure, and Biology.
  • https://doi.org/10.1021/acsmedchemlett.6c00080Copy DOI Icon

When Potency Is Not Enough: Aligning Modality, Exposure, and Biology.

Show More
  • Abstract
  • Literature Map
  • References
  • Similar Papers
Abstract

Recent patent disclosures illustrate how modern medicinal chemistry advances by aligning biological insight with chemical modality, formulation rigor, and molecular measurement. Targeted protein degradation to overcome resistance, solid-state engineering to ensure sustained pathway suppression, and single-cell genomic profiling to resolve metastatic biology together demonstrate how therapeutic impact emerges when perturbation, delivery, and biological observability are coherently integrated.

Similar Papers
  • Research Article

Abstract CN07-01: Using CTCs to improve outcomes in SCLC: Single cell profiling, ex vivo cultures, and mouse models

  • Dec 01, 2015
  • Molecular Cancer Therapeutics
  • Caroline Dive
  • Research Article

Abstract P2-02-15: Discovery of putative circulating tumor cells through somatic mutation profile of epithelial cell adhesion molecule positive single cells from blood of metastatic breast cancer patients

  • Feb 15, 2016
  • Cancer Research
  • H-B Lee +12
  • Conference Article

Abstract 981: Degradation of immuno-oncology targets via proprietary PROTAC platform integrating DNA-encoded library technology and rational drug design

  • Jul 01, 2019
  • Cancer Chemistry
  • Jannik N Andersen +10
  • Research Article
  • Citations3

Single-cell genomic profiling to study regeneration

  • Jul 24, 2024
  • Current Opinion in Genetics & Development
  • Ashley Maynard +2
  • Front Matter
  • Citations13

The key role of ubiquitination and sumoylation in signaling and cancer: a research topic

  • Dec 05, 2012
  • Frontiers in Oncology
  • Wenyi Wei +1
  • Research Article
  • Citations15

A heterobifunctional molecule recruits cereblon to an RNA scaffold and activates its PROTAC function

  • Sep 29, 2022
  • Cell Reports Physical Science
  • Yan Xu +10
  • Research Article
  • Citations419

Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing

  • Jan 01, 2018
  • Cell
  • Anna K Casasent +9
  • Research Article
  • Citations8

Targeted protein degradation: from small molecules to complex organelles-a Keystone Symposia report.

  • Jan 08, 2022
  • Annals of the New York Academy of Sciences
  • Jennifer Cable +31
  • Research Article

Abstract 6042: CBP-8008: A first-in-class targeted pan-Bet protein degradation therapy using bi-specific XDC (Bi-XDC) technology for TNBC and mCRPC

  • Mar 22, 2024
  • Cancer Research
  • Tao Wang +4
  • Preprint Article

Data from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS<sup>G12C</sup> Inhibition

  • Mar 31, 2023
  • Meagan B Ryan +7
  • Preprint Article

Data from EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i>-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

  • Apr 03, 2023
  • Ryan B Corcoran +15
  • Supplementary Content
  • Citations21

Artificial Intelligence in Colorectal Cancer: From Patient Screening over Tailoring Treatment Decisions to Identification of Novel Biomarkers

  • Jun 12, 2024
  • Digestion
  • Nic Gabriel Reitsam +4
  • Research Article
  • Citations5

Phenotypic Screening for Targeted Protein Degradation: Strategies, Challenges, and Emerging Opportunities.

  • Aug 28, 2025
  • Journal of medicinal chemistry
  • Baoli Ding +6
  • Research Article

PROTACs as novel therapeutics against Mycobacterium tuberculosis: Current progress and future directions.

  • Apr 01, 2026
  • European journal of medicinal chemistry
  • Deepthi Ramesh +1
  • Research Article
  • Citations41

Novel approaches to targeted protein degradation technologies in drug discovery

  • Mar 11, 2023
  • Expert Opinion on Drug Discovery
  • Yu Xue +2
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.